The end of the beginning: oncolytic virotherapy achieves clinical proof-of-concept.
D000256:Adenoviridae / Q000235:genetics; D000260:Adenoviruses, Human / Q000235:genetics*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D017326:Clinical Trials, Phase III as Topic / Q000639:trends; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000628:therapy* / Q000821:virology; D006801:Humans; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy / Q000628:therapy* / Q000821:virology; D050130:Oncolytic Virotherapy / Q000639:trends; D050504:Oncolytic Viruses / Q000235:genetics*; D014765:Viral Vaccines
D000970:Antineoplastic Agents; D014765:Viral Vaccines; C464532:dl1520